CD133+, CD166+ CD44+, and CD24+ CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines

Stem Cells Translational Medicine

Volumn 1, Issue 8, 2012, Pages 592-603

  Muraro, Manuele Giuseppe ^a   Mele, Valentina ^a   Däster, Silvio ^a,b   Han, Junyi ^a,c   Heberer, Michael ^a   Spagnoli, Giulio Cesare ^a   Iezzi, Giandomenica ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c TONGJI UNIVERSITY   (China)

Author keywords

Cancer; Cancer cell lines; Cancer stem cells; Cell surface markers; Chemotherapy; Colorectal cancer

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD24 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; IRINOTECAN; OXALIPLATIN; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC ANTIMETABOLITE; GLYCOPROTEIN; ISOENZYME; LEUKOCYTE ANTIGEN; PEPTIDE; RETINAL DEHYDROGENASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ARTICLE; CANCER STEM CELL; CARCINOGENICITY; CELL EXPANSION; CELL POPULATION; CHEMOSENSITIVITY; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIDE POPULATION CELL; TUMOR SPHEROID; ANIMAL; COLORECTAL TUMOR; DRUG EFFECT; DRUG SCREENING; METABOLISM; MOUSE MUTANT; MULTICELLULAR SPHEROID; NONOBESE DIABETIC MOUSE; PATHOLOGY; TRANSPLANTATION; TUMOR CELL CULTURE;

ACTIVATED-LEUKOCYTE CELL ADHESION MOLECULE; ANIMALS; ANTIGENS, CD; ANTIGENS, CD24; ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; COLORECTAL NEOPLASMS; FLUOROURACIL; GLYCOPROTEINS; HUMANS; ISOENZYMES; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PEPTIDES; PHENOTYPE; RETINAL DEHYDROGENASE; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR STEM CELL ASSAY;

EID: 84872116140     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0003     Document Type: Article

References (47)

1. Polyak K, Hahn WC. Roots and stems: Stem cells in cancer. Nat Med 2006;12:296-300.
2. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
3. Clevers H. The cancer stem cell: Premises, promises and challenges. Nat Med 2011;17: 313-319.
4. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: Models and concepts. Annu Rev Med 2007;58:267-284.
5. Gires O. Lessons from common markers of tumor-initiating cells in solid cancers. Cell Mol Life Sci 2011;68:4009-4022.
6. O'Brien CA, Pollett A, Gallinger S et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human coloncancer-initiating cells. Nature 2007;445:111-115.
8. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104:10158-10163.
9. Yeung TM, Gandhi SC, Wilding JL et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci USA 2010; 107:3722-3727.
10. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
11. Zhang M, Behbod F, Atkinson RL et al. Identification of tumor-initiating cells in a p53- null mouse model of breast cancer. Cancer Res 2008;68:4674-4682.
12. Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-760.
13. Ginestier C, Hur MH, Charafe-Jauffret E et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007;1:555-567.
14. Bleau AM, Hambardzumyan D, Ozawa T et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009;4:226-235.
15. Hirschmann-Jax C, Foster AE, Wulf GG et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 2004;101:14228-14233.
16. Patrawala L, Calhoun T, SchneiderBroussard R et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2 and ABCG2 cancer cells are similarly tumorigenic. Cancer Res 2005;65:6207-6219.
17. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-823.
18. Zhou BB, Zhang H, Damelin M et al. Tumour-initiating cells: Challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-823.
19. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008;10:R25.
20. Charafe-Jauffret E, Ginestier C, Iovino F et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009;69:1302-1313.
21. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004;101:781-786.
22. Hermann PC, Huber SL, Herrler T et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313-323.
23. Ieta K, Tanaka F, Haraguchi N et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008;15:638-648.
24. Sandberg R, Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). Proc Natl Acad Sci USA 2005;102:2052-2057.
25. van Staveren WC, Solis DY, Hebrant A et al. Human cancer cell lines: Experimental models for cancer cells in situ? For cancer stem cells? Biochim Biophys Acta 2009;1795:92-103.
26. Gupta PB, Onder TT, Jiang G et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009; 138:645-659.
27. Kreso A, O'Brien CA. Colon cancer stem cells. Curr Protoc Stem Cell Biol 2008;Chapter 3:Unit 3.1.
28. Ghosh S, Spagnoli GC, Martin I et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: A high density oligonucleotide array study. J Cell Physiol 2005;204:522-531.
29. Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-78.
30. Goodell MA, Brose K, Paradis G et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996;183:1797-1806.
31. Scudiero DA, Shoemaker RH, Paull KD et al. Evaluation of a soluble tetrazolium/ formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833.
32. Reynolds BA, Rietze RL. Neural stem cells and neurospheres-re-evaluating the relationship. Nat Methods 2005;2:333-336.
33. Huang EH, Hynes MJ, Zhang T et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-3389.
34. Dylla SJ, Beviglia L, Park IK et al. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008;3:e2428.
35. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402.
36. Li X, Lewis MT, Huang J et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100: 672-679.
37. Chu P, Clanton DJ, Snipas TS et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124:1312-1321.
38. Du L, Wang H, He L et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-6760.
39. Kai K, Nagano O, Sugihara E et al. Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. Cancer Sci 2009;100:2275-2282.
40. Stuelten C, Mertins S, Busch J et al. Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. STEM CELLS 2010;28:649-660.
41. Haraguchi N, Utsunomiya T, Inoue H et al. Characterization of a side population of cancer cells from human gastrointestinal system. STEM CELLS 2006;24:506-513.
42. Burkert J, Otto WR, Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. J Pathol 2008;214:564-573.
43. Vermeulen L, De Sousa E, van der Melo HM et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010;12:468-476.
44. Jaksch M, Munera J, Bajpai R et al. Cell cycle-dependent variation of a CD133 epitope in human embryonic stem cell, colon cancer, and melanoma cell lines. Cancer Res 2008;68: 7882-7886.
45. Mariotti E, Gemei M, Mirabelli P et al. The percentage of CD133 cells in human colorectal cancer cell lines is influenced by Mycoplasma hyorhinis infection 4. BMC Cancer 2010;10:120.
46. Barker N, Ridgway RA, van Es JH et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-611.
47. Dittfeld C, Dietrich A, Peickert S et al. CD133 expression is not selective for tumorinitiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010;94:375-383.